Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1. Profiles of the top 50 mRNA probes of the first gene signature identified in the South African cohort. ... Figure 1. Profiles of the top 50 mRNA.

Published byΤύχων Βούλγαρης Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1. Profiles of the top 50 mRNA probes of the first gene signature identified in the South African cohort. ... Figure 1. Profiles of the top 50 mRNA."— Presentation transcript:

1 Figure 1. Profiles of the top 50 mRNA probes of the first gene signature identified in the South African cohort. ... Figure 1. Profiles of the top 50 mRNA probes of the first gene signature identified in the South African cohort. Expression ratios for the top 50 mRNA probes of the first gene signature (HR<sup>+</sup> HPV and CIN1/2/3 gene signature) able to differentiate group C from groups A and B. The first gene signature consisted of 272 mRNA probes with FDR <15% and fold change >1.5 in the comparison of group A + B with group C and P < 0.05 in the comparisons of groups A, B and A + B with group C. Shown are the top 25 mRNA probes that displayed <−1.66-fold change and the top 25 mRNA probes that displayed >1.98-fold change in expression ratios. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press. All rights reserved. For Permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Carcinogenesis, Volume 40, Issue 2, 26 October 2018, Pages 225–233, The content of this slide may be subject to copyright: please see the slide notes for details.

2 Figure 2. Profiles of the 22 mRNA probes of the second gene signature identified in the South African cohort. ... Figure 2. Profiles of the 22 mRNA probes of the second gene signature identified in the South African cohort. Expression ratios for the 22 mRNA probes of the second gene signature (HR HPV-free and cervical histopathology-free) able to differentiate group A from groups B and C. The second gene signature consisted of 22 genes not represented in the first gene signature (n = 272 genes), with FDR <15% and fold change >1.5 in the comparison of group A with group C and with P < 0.05 in the comparison of group A with group B. Shown are all 22 genes of the signature. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press. All rights reserved. For Permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Carcinogenesis, Volume 40, Issue 2, 26 October 2018, Pages 225–233, The content of this slide may be subject to copyright: please see the slide notes for details.

3 Figure 3. Profiles of the 81 mRNA probes of the third gene signature identified in the South African cohort. Expression ... Figure 3. Profiles of the 81 mRNA probes of the third gene signature identified in the South African cohort. Expression ratios for the 81 mRNA probes of the third gene signature (HR<sup>+</sup> HPV and cervical histopathology-free) able to differentiate group B from groups A and C. The third gene signature identified 81 genes not represented in the first gene signature (n = 272 genes), with FDR <15% and fold change >1.5 in the comparison of group B with group C and with P < 0.05 in the comparison of group A with group B. Shown are the top 25 mRNA probes that displayed <−1.66-fold change and the top 24 mRNA probes that displayed >1.98-fold change in expression ratios. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press. All rights reserved. For Permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Carcinogenesis, Volume 40, Issue 2, 26 October 2018, Pages 225–233, The content of this slide may be subject to copyright: please see the slide notes for details.

4 Figure 4. Principal component analysis of mRNA probes in the Botswana cohort. Principal component analysis using the Figure 4. Principal component analysis of mRNA probes in the Botswana cohort. Principal component analysis using the informative mRNA probes [i.e. genes with good detection in all samples (i.e. detection P < 0.05 in all samples), >1.2-fold change between any two samples and background level of expression about 82]. Data are shown for each patient from group R (i.e. women with post-LEEP disease recurrence/relapse, indicated with black circles) and group NR (i.e. women without post-LEEP disease recurrence/relapse, indicated with white squares) of the Botswana cohort. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press. All rights reserved. For Permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Carcinogenesis, Volume 40, Issue 2, 26 October 2018, Pages 225–233, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 1. Profiles of the top 50 mRNA probes of the first gene signature identified in the South African cohort. ... Figure 1. Profiles of the top 50 mRNA."

Similar presentations

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 Flowchart of our CIS cohort considering patients (A) and eyes (B) as statistical unit. Unless provided in the caption above, the following copyright.

Figure 1 Flowchart of our CIS cohort considering patients (A) and eyes (B) as statistical unit. Unless provided in the caption above, the following copyright.
Figure 1 Data-selection process

Figure 1 Data-selection process
Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Flow diagram detailing the systematic review process.
Fig. 1. Axial, coronal, and sagittal views of post hoc results (mean gFA) demonstrating significant differences ... Fig. 1. Axial, coronal, and sagittal.

Fig. 1. Axial, coronal, and sagittal views of post hoc results (mean gFA) demonstrating significant differences ... Fig. 1. Axial, coronal, and sagittal.
Figure 1 Schematic representation of the experimental design.

Figure 1 Schematic representation of the experimental design.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1 Mechanism of mortality benefit associated with radial access
Figure 1. Linkage analyses of the SNPs in the MRE11 gene and haplotype blocks. Haplotype blocks were defined for all ... Figure 1. Linkage analyses of.

Figure 1. Linkage analyses of the SNPs in the MRE11 gene and haplotype blocks. Haplotype blocks were defined for all ... Figure 1. Linkage analyses of.
Figure 1. Multivariable-adjusted hazard ratios (solid line) for incident chronic obstructive pulmonary disease as a ... Figure 1. Multivariable-adjusted.

Figure 1. Multivariable-adjusted hazard ratios (solid line) for incident chronic obstructive pulmonary disease as a ... Figure 1. Multivariable-adjusted.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 Mean (±SE) egg investment in female zebra finches shortly after a second injection with either tetanus toxoid ... Figure 1 Mean (±SE) egg investment.

Figure 1 Mean (±SE) egg investment in female zebra finches shortly after a second injection with either tetanus toxoid ... Figure 1 Mean (±SE) egg investment.
Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.

Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.
AHA: American Heart Association; ALT: ...

AHA: American Heart Association; ALT: ...
Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.

Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.
Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.
Source: Figure created by the author based on data ...

Source: Figure created by the author based on data ...
bDMARD: biologic DMARD.

bDMARD: biologic DMARD.
Black: diagnosis ... Black: diagnosis from any department; grey: diagnosis at a rheumatology department. Unless provided in the caption above, the following.

Black: diagnosis ... Black: diagnosis from any department; grey: diagnosis at a rheumatology department. Unless provided in the caption above, the following.

Similar presentations

Ads by Google